ERBB2 and melanoma: In melanoma and triple-negative breast cancer, MEK inhibition led to increased activation of Axl and therefore increased tumor burden, while hetero-dimerization of Axl and Her2 reduced the response to Trastuzumab in Her2-positive breast cancer, highlighting the role of Axl in mediating resistance against targeted therapy (15, 16).